Financial Toxicity and Cost-Management Behaviors Among Patients with Myelodysplastic Syndromes

Rogers, Kimberly Papay; Miller, M. F.; Fortune, Erica E.; Iraca, Tracey; Goldberg, Stuart L.

doi:10.1182/blood-2022-162378

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The routine assessment of PROs in clinical trials will better characterize the therapeutic impact on our patients and their caregivers, who report a poor QOL and mental health burden 91 . Financial toxicity is described in approximately 40% of patients 92 and is a significant source of distress for patients with MDS. Investigations into the role financial toxicity on QOL and mental health are essential given the high cost of novel therapies in the current era 93 …”

Section: Response Assessment For Hr-mdsmentioning

confidence: 99%

Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms

et al. 2023

View full text Add to dashboard Cite

Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast burden reduction and hematologic recovery. Despite revision of the IWG criteria in 2006, correlation between IWG-defined responses and patient-focused outcomes, including long-term benefits, remains limited and has potentially contributed to failures of several phase III clinical trials. Several IWG 2006 criteria also lacked clear definitions leading to problems in practical applications and interobserver and intraobserver consistency of response reporting. Although the 2018 revision addressed lower-risk MDS, the most recent update in 2023 redefined responses for higher-risk MDS and has set out to provide clear definitions to enhance consistency while focusing on clinically meaningful outcomes and patient-centered responses. In this review, we analyze the evolution of the MDS response criteria, limitations, and areas of improvement.

show abstract

Section: Response Assessment For Hr-mdsmentioning

confidence: 99%

Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms

et al. 2023

View full text Add to dashboard Cite

show abstract

Development and validation of FinTox: A new screening tool to assess cancer‐related financial toxicity

Badr,

Han,

Mims

2024

Cancer Medicine

View full text Add to dashboard Cite

PurposeThis study aimed to develop and validate FinTox, a concise tool for screening and managing financial toxicity in oncology settings.MethodsDevelopment involved qualitative interviews with healthcare providers and patients, and feedback from a 7‐member expert panel resulting in a 5‐item measure that evaluates financial strain, psychological responses, and care modifications. Psychometric evaluations examined factor structure, internal consistency, test–retest reliability, and concurrent and convergent validity. Associations between FinTox scores and sociodemographic/medical factors were also analyzed using univariate and multivariable regression models.ResultsTwelve healthcare providers and 20 patients were interviewed, and 268 patients (69.8% female, 47.4% non‐Hispanic White) completed surveys including FinTox, the Comprehensive Score for Financial Toxicity (COST), health‐related quality of life (HRQOL) measures, and sociodemographic questions. FinTox demonstrated excellent internal consistency (Cronbach's alpha = 0.90) and test–retest reliability (ICC = 0.95). Significant correlations with the COST (r = −0.62, p < 0.001) and HRQOL measures corroborated content and convergent validity. Diagnostic accuracy was evidenced by a sensitivity of 72.3%, specificity of 85.2%, positive predictive value of 83.2%, and negative predictive value of 70.3%. Higher FinTox scores were also associated with receiving care at a safety‐net hospital, Black race, household income <600% of the federal poverty level, and Stage 4 cancer.ConclusionFinTox's robust psychometric properties and diagnostic accuracy position it as a reliable tool for detecting financial toxicity. Future research should evaluate its responsiveness to changes over time and integration into clinical workflows.

show abstract

Financial Toxicity and Cost-Management Behaviors Among Patients with Myelodysplastic Syndromes

Cited by 2 publications

References 0 publications

Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms

Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms

Development and validation of FinTox: A new screening tool to assess cancer‐related financial toxicity

Contact Info

Product

Resources

About